MX362902B - Compuestos novedosos con actividades triples de trombólisis, anti-trombótica y depuración de radicales y síntesis, nano-estructura y uso de los mismos. - Google Patents
Compuestos novedosos con actividades triples de trombólisis, anti-trombótica y depuración de radicales y síntesis, nano-estructura y uso de los mismos.Info
- Publication number
- MX362902B MX362902B MX2015015924A MX2015015924A MX362902B MX 362902 B MX362902 B MX 362902B MX 2015015924 A MX2015015924 A MX 2015015924A MX 2015015924 A MX2015015924 A MX 2015015924A MX 362902 B MX362902 B MX 362902B
- Authority
- MX
- Mexico
- Prior art keywords
- thrombolysis
- antithrombotic
- radical scavenging
- new compounds
- nano
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 3
- 230000002537 thrombolytic effect Effects 0.000 title abstract 3
- 230000002292 Radical scavenging effect Effects 0.000 title abstract 2
- 230000002785 anti-thrombosis Effects 0.000 title abstract 2
- 239000003146 anticoagulant agent Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000002086 nanomaterial Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un compuesto que tiene simultáneamente actividades triples de trombólisis, anti-trombosis y depuración de radicales libres, así como el método de preparación, composición y sus aplicaciones; el compuesto está representado por la fórmula I que se muestra a continuación: (ver Fórmula) en donde las definiciones de T, Q, R1 y R2 se describen en la presente; el compuesto de la presente invención tiene simultáneamente funciones triples de trombólisis, depuración de radicales libres y trombo-direccionamiento/anti-trom bosis; la presente invención también se refiere a una composición farmacéutica que comprende el compuesto, y un método de preparación y una nanoestructura del compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310225330 | 2013-06-05 | ||
| PCT/CN2014/079098 WO2014194809A1 (zh) | 2013-06-05 | 2014-06-03 | 具有溶栓、抗栓和自由基清除三重活性的新型化合物、其合成、纳米结构和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015015924A MX2015015924A (es) | 2016-04-06 |
| MX362902B true MX362902B (es) | 2019-02-22 |
Family
ID=52007559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015924A MX362902B (es) | 2013-06-05 | 2014-06-03 | Compuestos novedosos con actividades triples de trombólisis, anti-trombótica y depuración de radicales y síntesis, nano-estructura y uso de los mismos. |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US9890193B2 (es) |
| EP (1) | EP3006454B1 (es) |
| JP (1) | JP6510500B2 (es) |
| KR (1) | KR102204781B1 (es) |
| CN (1) | CN104231046B (es) |
| AU (1) | AU2014277416B2 (es) |
| BR (1) | BR112015027164B1 (es) |
| CA (1) | CA2914004C (es) |
| CY (1) | CY1123976T1 (es) |
| DK (1) | DK3006454T3 (es) |
| ES (1) | ES2847934T3 (es) |
| HR (1) | HRP20210566T1 (es) |
| HU (1) | HUE053351T2 (es) |
| LT (1) | LT3006454T (es) |
| MX (1) | MX362902B (es) |
| PH (1) | PH12015502684B1 (es) |
| PL (1) | PL3006454T3 (es) |
| PT (1) | PT3006454T (es) |
| RS (1) | RS61606B1 (es) |
| RU (1) | RU2660901C2 (es) |
| SI (1) | SI3006454T1 (es) |
| TW (1) | TWI633889B (es) |
| WO (1) | WO2014194809A1 (es) |
| ZA (1) | ZA201507237B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106608905B (zh) * | 2015-10-22 | 2020-10-16 | 彭莉 | 四氢异喹啉-3-甲酰-k(grpak)rgdv,其合成,活性及应用 |
| CN106608902A (zh) * | 2015-10-22 | 2017-05-03 | 彭莉 | 二羟基二甲基四氢异喹啉-3-甲酰-Lys(Lys),其合成,活性及应用 |
| JP6663774B2 (ja) | 2016-03-30 | 2020-03-13 | 東京エレクトロン株式会社 | 基板搬送方法及び基板処理システム |
| BR112022005327A2 (pt) * | 2019-09-25 | 2022-06-14 | Lumosa Therapeutics Co Ltd | Composição farmacêutica compreendendo conjugado de peptídeo trombolítico-tetraidroisoquinolina |
| KR20230041966A (ko) * | 2020-05-15 | 2023-03-27 | 신헬릭스 | 펩티드 스캐폴드, 이를 제조하기 위한 방법, 및 가용성 지지체로서의 이의 용도 |
| CA3212069A1 (en) | 2021-03-22 | 2022-09-29 | Jung-Chin Lin | Dc009 for treating acute ischemic stroke |
| CN115403653B (zh) * | 2022-05-19 | 2024-08-06 | 首都医科大学 | D(+)-β-(3,4-二羟基苯基)-乳酰-Pro-Ala-Lys,其合成及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5222632B2 (es) * | 1972-08-22 | 1977-06-18 | ||
| US7291619B2 (en) | 2001-01-23 | 2007-11-06 | Eli Lilly And Company | Melanocortin receptor agonists |
| CA2473036A1 (en) | 2002-01-23 | 2003-07-31 | Paul Leslie Ornstein | Melanocortin receptor agonists |
| CA2508891A1 (en) * | 2002-12-23 | 2004-07-22 | Janssen Pharmaceutica, N.V. | Heteroaryl peptidomimetics as thrombin receptor antagonists |
| CN101190895B (zh) | 2006-11-30 | 2010-05-26 | 首都医科大学 | N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用 |
| CN101190941B (zh) * | 2006-11-30 | 2010-12-01 | 首都医科大学 | 具有溶血栓活性的多肽、其制备方法及应用 |
| CN101200493B (zh) | 2006-12-11 | 2011-11-09 | 首都医科大学 | （3s）-n-（l-氨基酰）-1，2，3，4-四氢异喹啉-3-羧酸、其制备方法及应用 |
| CN101497651B (zh) | 2008-01-30 | 2012-06-27 | 首都医科大学 | 具有溶血栓活性的化合物、其制备方法、其应用 |
| CN102241740B (zh) * | 2008-01-30 | 2014-02-19 | 首都医科大学 | 具有溶血栓活性的化合物、其制备方法、其应用 |
| CN101899084B (zh) | 2009-05-26 | 2012-09-05 | 首都医科大学 | (3s)-1,2,3,4-四氢异喹啉-3-羧酸三肽缀合物及其制备方法和应用 |
| CN102120727B (zh) | 2010-01-07 | 2013-08-28 | 首都医科大学 | N-[(3s)-n-氨基酰-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸及其合成方法和应用 |
| CN102127097A (zh) | 2010-01-15 | 2011-07-20 | 首都医科大学 | N-（3s-1,2,3,4-四氢异喹啉-3-甲酰基）氨基酸铜络合物及其制备方法和应用 |
| CN102477068B (zh) | 2010-11-30 | 2013-07-24 | 首都医科大学 | 用于制备溶血栓药物的氨基酸衍生物及其制备方法和应用 |
| CA2851810C (en) * | 2011-10-14 | 2020-01-07 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| CN103145797B (zh) | 2011-12-07 | 2015-05-20 | 首都医科大学 | [(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]-Lys修饰的RGD四肽,其合成和在医学中的应用 |
| CN103450338B (zh) | 2012-05-29 | 2016-08-24 | 首都医科大学 | 杂环羧酸修饰的胸腺五肽，其制备，抗肿瘤作用和应用 |
| CN103450330B (zh) * | 2012-06-01 | 2016-05-25 | 首都医科大学 | 二羟基四氢异喹啉-3-甲酰氨基酸、其合成、抗血栓作用和应用 |
| CN102887941A (zh) * | 2012-09-05 | 2013-01-23 | 永光制药有限公司 | Pak/咪唑啉/rgd三元缀合物及其制备方法和用途 |
| CN103665107B (zh) * | 2012-09-05 | 2017-07-14 | 上海晟顺生物科技有限公司 | 同时具溶血栓、清除自由基和血栓靶向功能的新颖化合物及其制备方法和用途 |
-
2014
- 2014-06-03 KR KR1020157035673A patent/KR102204781B1/ko active IP Right Grant
- 2014-06-03 JP JP2016517144A patent/JP6510500B2/ja active Active
- 2014-06-03 RU RU2015147247A patent/RU2660901C2/ru active
- 2014-06-03 WO PCT/CN2014/079098 patent/WO2014194809A1/zh active Application Filing
- 2014-06-03 ES ES14807973T patent/ES2847934T3/es active Active
- 2014-06-03 MX MX2015015924A patent/MX362902B/es active IP Right Grant
- 2014-06-03 SI SI201431789T patent/SI3006454T1/sl unknown
- 2014-06-03 PL PL14807973T patent/PL3006454T3/pl unknown
- 2014-06-03 EP EP14807973.4A patent/EP3006454B1/en active Active
- 2014-06-03 PT PT148079734T patent/PT3006454T/pt unknown
- 2014-06-03 LT LTEP14807973.4T patent/LT3006454T/lt unknown
- 2014-06-03 BR BR112015027164-2A patent/BR112015027164B1/pt active IP Right Grant
- 2014-06-03 CN CN201410242169.8A patent/CN104231046B/zh active Active
- 2014-06-03 RS RS20210349A patent/RS61606B1/sr unknown
- 2014-06-03 DK DK14807973.4T patent/DK3006454T3/da active
- 2014-06-03 CA CA2914004A patent/CA2914004C/en active Active
- 2014-06-03 AU AU2014277416A patent/AU2014277416B2/en active Active
- 2014-06-03 HU HUE14807973A patent/HUE053351T2/hu unknown
- 2014-06-04 TW TW103119375A patent/TWI633889B/zh active
-
2015
- 2015-09-30 ZA ZA201507237A patent/ZA201507237B/en unknown
- 2015-12-01 PH PH12015502684A patent/PH12015502684B1/en unknown
- 2015-12-02 US US14/956,723 patent/US9890193B2/en active Active
-
2018
- 2018-01-03 US US15/861,300 patent/US10351594B2/en active Active
-
2019
- 2019-07-09 US US16/506,674 patent/US20200055895A1/en not_active Abandoned
-
2021
- 2021-03-22 CY CY20211100244T patent/CY1123976T1/el unknown
- 2021-04-08 US US17/225,775 patent/US20210355163A1/en not_active Abandoned
- 2021-04-09 HR HRP20210566TT patent/HRP20210566T1/hr unknown
-
2023
- 2023-03-09 US US18/181,494 patent/US20230312644A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502684A1 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
| AU2016202535B2 (en) | Fused heterocyclic compounds as sodium channel modulators | |
| GEP201606555B (en) | Compounds and compositions for modulating egfr activity | |
| MX2016006336A (es) | Compuestos pirazolopirimidina. | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| NZ716840A (en) | Combination formulation of two antiviral compounds | |
| MX351812B (es) | Derivados de piridona. | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| PH12018500377A1 (en) | Novel annelated benzamides | |
| MX2015010106A (es) | Moduladores de la proteina activadora de 5-lipoxigenasa. | |
| PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
| UA110128C2 (uk) | Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди | |
| MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
| MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| EA201590475A1 (ru) | Тетрациклиновые соединения | |
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| PH12016500461A1 (en) | Polyethylene glycol-containing composition | |
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| WO2013106756A3 (en) | Antimicrobial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |